Klotho Neurosciences (NASDAQ:KLTO) Shares Up 0.6% – Should You Buy?

Klotho Neurosciences, Inc. (NASDAQ:KLTO)’s stock price was up 0.6% during mid-day trading on Thursday . The company traded as high as $0.3950 and last traded at $0.3626. Approximately 667,737 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 779,516 shares. The stock had previously closed at $0.3606.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Klotho Neurosciences currently has an average rating of “Sell”.

Klotho Neurosciences Trading Up 7.0%

The firm has a market cap of $28.15 million, a P/E ratio of -1.21 and a beta of 10.05. The company’s fifty day moving average price is $0.49 and its two-hundred day moving average price is $0.77.

Klotho Neurosciences (NASDAQ:KLTO) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.05) earnings per share for the quarter.

Institutional Trading of Klotho Neurosciences

An institutional investor recently bought a new position in Klotho Neurosciences stock. Jane Street Group LLC purchased a new stake in Klotho Neurosciences, Inc. (NASDAQ:KLTO) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned about 0.05% of Klotho Neurosciences at the end of the most recent reporting period. Institutional investors own 20.07% of the company’s stock.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.